AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AstraZeneca (AZN) Acquires Biologics Manufacturing Facility from Amgen (AMGN)
September 11, 2015 7:02 AM EDTAstraZeneca (NYSE: AZN) added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc (Nasdaq: AMGN). Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the companys extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility immediately to... More
